<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href="http://www.blogger.com/styles/atom.css" type="text/css"?><feed xmlns='http://www.w3.org/2005/Atom' xmlns:openSearch='http://a9.com/-/spec/opensearchrss/1.0/' xmlns:blogger='http://schemas.google.com/blogger/2008' xmlns:georss='http://www.georss.org/georss' xmlns:gd="http://schemas.google.com/g/2005" xmlns:thr='http://purl.org/syndication/thread/1.0'><id>tag:blogger.com,1999:blog-5243484110268352177</id><updated>2024-10-06T22:17:46.497-07:00</updated><category term="Blood test"/><category term="Cardiology"/><category term="Diagnostics"/><category term="C.M.Cardiology"/><category term="Pharmacology"/><category term="C.M.Pulmology"/><category term="Pediatrics"/><category term="C.M Hematology"/><category term="Dietetics and Nutrition"/><category term="Endocrinology"/><category term="Neurology"/><category term="Oncology"/><category term="Orthopaedics"/><category term="Dermatology"/><category term="Gastroenterology"/><category term="Hematology"/><category term="Infectious Diseases"/><category term="Nephrology"/><category term="Obstetrics and Gynecology"/><category term="C.M Infectology"/><category term="Diabetology"/><category term="Otolaryngology"/><category term="Pneumology"/><category term="Rheumatology"/><category term="Allergology"/><category term="Andrology"/><category term="CARDIOTHORACIC SURGERY"/><category term="Clinical Medicine"/><category term="General Surgery"/><category term="Geriatrics"/><category term="Immunology"/><category term="Palliative Care"/><category term="Psychology"/><category term="Radiology"/><category term="Urology"/><title type='text'>DOC Logic</title><subtitle type='html'></subtitle><link rel='http://schemas.google.com/g/2005#feed' type='application/atom+xml' href='http://doc-logic.blogspot.com/feeds/posts/default'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default?redirect=false'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/'/><link rel='hub' href='http://pubsubhubbub.appspot.com/'/><link rel='next' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default?start-index=26&amp;max-results=25&amp;redirect=false'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><generator version='7.00' uri='http://www.blogger.com'>Blogger</generator><openSearch:totalResults>206</openSearch:totalResults><openSearch:startIndex>1</openSearch:startIndex><openSearch:itemsPerPage>25</openSearch:itemsPerPage><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-4775712968808957373</id><published>2013-01-25T13:18:00.000-08:00</published><updated>2013-01-25T15:25:17.555-08:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Obstetrics and Gynecology"/><title type='text'>Vaccine Against Papillomavirus</title><summary type="text">

In the USA, every year, 500,000 cases of genital warts are discovered, caused in 90% of cases by type 6 and 11 Papillomavirus, while serotypes 16 and 18 are accountable for 70% of cervical cancers. Since 2006 a quadrivalent vaccine (HPV4) is available, containing all the 4 serotypes and put to the disposal of female population between 9 and 26 years of age. In October 2009, a new vaccine has </summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/4775712968808957373'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/4775712968808957373'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2011/01/vaccine-against-papillomavirus.html' title='Vaccine Against Papillomavirus'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj-EdctZK4pwHRTzY-QX2GG7vckYKuCj_kgKsNCa4xBORWtwWhbEHnWOSrDfS6a8apfmjqIcuz_D1Co9BSSa3pg-MXYoHVP9-VU7I-TfVm67bcwHKEybLYr8qfahCNsxg18PVV_OAw_UGSu/s72-c/9.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-5595101688224156373</id><published>2012-01-25T13:52:00.000-08:00</published><updated>2012-01-25T13:52:46.858-08:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Obstetrics and Gynecology"/><title type='text'>Pregnant Women Who Develop Life-Threatening Blood Clots Should Receive Aggressive Treatment</title><summary type="text">

Pregnant women who develop dangerous blood clots in the leg often forgo the most effective treatment for fear of harming the baby. Yet treatment to remove the clot is not only safe, it can prevent serious problems, including death, suggests research being presented at the 24thannual International Symposium on Endovascular Therapy (ISET).

Iliofemoral deep vein thrombosis (DVT) – a blood clot </summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/5595101688224156373'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/5595101688224156373'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2012/01/pregnant-women-who-develop-life.html' title='Pregnant Women Who Develop Life-Threatening Blood Clots Should Receive Aggressive Treatment'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiJbv-am-vX4N-bVVonLKocCVQcxGKat1-SneIf4Xo1RyM749iAHKbA0Yj6do8s94JexfQXuM0OKLujoXyZ0cwph_ECtVs0qvg3IzMiqCJb00_T4vnzHSfz0GfxdnkaPTeSCWskqdSlYN5Y/s72-c/Pregnant-and-Legs-588x338.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-2166627939987751622</id><published>2011-05-16T11:37:00.000-07:00</published><updated>2011-05-16T11:37:12.255-07:00</updated><title type='text'>New Method Enables Design, Production Of Extremely Novel Drugs</title><summary type="text">



A new chemical synthesis method based on a catalyst worth many times the price of gold and providing a far more efficient and economical method than traditional ones for designing and manufacturing extremely novel pharmaceutical compounds is described by its University at Buffalo developers in a review article in the journal Nature.
The chemistry, the basis of a new biotech startup company </summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/2166627939987751622'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/2166627939987751622'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2011/05/new-method-enables-design-production-of.html' title='New Method Enables Design, Production Of Extremely Novel Drugs'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhTs-pDMQc1Opin8xogN1zFUKIo9EM6d_T3HRnOLFhaLQISm18maZ4bP4vVUS-hMWSLaoJxERVRb81hN4BGyR0n53X8PQr4v7bGQ1CAtV4ORCLdkaW3esLzEGMzPeruKyeYahXZyUHHm6qT/s72-c/080123161246.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-2156174303621767272</id><published>2011-04-27T12:23:00.000-07:00</published><updated>2011-04-27T12:25:23.662-07:00</updated><title type='text'>CARDIOVASCULAR PHARMACOLOGY</title><summary type="text">

1. Inotropes 

A. Digitalis 

1) Inhibit Na-K-ATPase - positive inotropic effect 

2) Parasympathomimetic and anti-adrenergic mechanisms 

3) Drug interaction - Quinidine, Verapamil, Amiodarone 

4) Conditions that increase sensitivity 




2. Inotropes, Vasoconstricting 

A. Dopamine 

1) Low doses - D1 receptors in renal vasculature 

2) Increasing doses - b-1 receptors activated 

3) High </summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/2156174303621767272'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/2156174303621767272'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2011/04/cardiovascular-pharmacology.html' title='CARDIOVASCULAR PHARMACOLOGY'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author></entry><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-4864336021048983891</id><published>2011-04-27T10:02:00.000-07:00</published><updated>2011-04-27T10:02:16.868-07:00</updated><title type='text'>Echocardiography</title><summary type="text">

1. High frequency ultrasound = 2.0 - 7.5 MHz 

A. Adults = 2.0 - 2.5 MHz 

B. Pediatric = 3.0 - 5.0 MHz 

C. TEE = 3.5 - 7.5 MHz 

D. M-mode &quot;ice pick view&quot; 

E. 2D sector scanning 

F. Doppler effect 

G. Color flow imaging 

&amp;nbsp;

&amp;nbsp;

2. Standard Transducer Positions 

A. Transthoracic long 

&amp;nbsp;



B. Transthoracic 90o short axis 

&amp;nbsp;



C. Parasternal long 

&amp;nbsp;



D. </summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/4864336021048983891'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/4864336021048983891'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2011/04/echocardiography.html' title='Echocardiography'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjOJowB0zcmw1_oi4jxOwtuj1jW33S4S_-tAutxYOJcUVwi1P6TemQ8cI-bfePTjygs4C79XlcYSUnbHZffaDZhN60n5xlnchwWMDJ0aThlk2La0g7p5qjx4BcVK2qljSeFRgfKLBkHGdR8/s72-c/ctsnecho1.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-3960409302952530451</id><published>2011-04-26T08:13:00.001-07:00</published><updated>2011-04-26T08:13:59.578-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Pneumology"/><title type='text'>Silent Pulmonary Embolism in DVT</title><summary type="text">



According to post-mortem results, it has been seen that the diagnosis of pulmonary embolism, even in cases of important extension, is often not performed, so researchers have wondered whether pulmonary embolism screening should be performed in patients with deep venous thrombosis (DVT), even in the absence of respiratory symptoms. A systematic review has been performed on 28 prospective </summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/3960409302952530451'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/3960409302952530451'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2011/04/silent-pulmonary-embolism-in-dvt.html' title='Silent Pulmonary Embolism in DVT'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgeIrS6sW9m6s1YNDb084cq-Hnf-WmVMGHCvpnrVTbNwdr1ysyl3sXkQ_NZUFZJXivIXgVsz5ZyJIfx43oVMPtJnU-K-VLtgPwmN6-qenpZpJr5RC6cjXnOKvOSlvYx7rDu5SHJ6XbJ4Si5/s72-c/pulmonary-embolism-427x500.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-1018423218976335608</id><published>2011-04-26T08:13:00.000-07:00</published><updated>2011-11-14T15:39:02.348-08:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Orthopaedics"/><title type='text'>Thrombotic Prophylaxis in Orthopedic Surgery</title><summary type="text">



In patients undergoing orthopedic surgery, a long-acting anti-thrombotic prophylaxis is usually performed, but is this practice really useful and necessary? Through a multinational trial, sponsored by pharmaceutical industry, the efficacy of a long-term prophylaxis in acute patients has been assessed: everybody has been treated with enoxaparin for 10 days, then all have been randomized to </summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/1018423218976335608'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/1018423218976335608'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2011/04/thrombotic-prophylaxis-in-orthopedic.html' title='Thrombotic Prophylaxis in Orthopedic Surgery'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgRpGcuurXBOoiClGLxPkq2yXdiELIjWCZll13ngz1quBIRywjQIa88jSR65mTMP1ZpPHWXxO18Ncbf9EeEx2pdD8y9jU6m2Wh_1vxjIFTJ9PKDirejniKBbxazHzG4W0DZN56OquIHgT5l/s72-c/advanced_orthopedics_low.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-8128010022994401298</id><published>2011-04-25T13:15:00.000-07:00</published><updated>2011-04-25T13:20:31.842-07:00</updated><title type='text'>Developmental Anatomy</title><summary type="text">
&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 1. Basic Principles 

A. Cardiovascular system is first functional system in embryo 

B. Blood circulation by 3 weeks (21 days) 

C. Heart </summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/8128010022994401298'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/8128010022994401298'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2011/04/developmental-anatomy.html' title='Developmental Anatomy'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIVrde5jptBeOhyR1mQ8NR8JiCKoKdbhV7lisNjFrv9bDpEyqUaUUIXiJsutHsv_nnBUKczmrNJawjoKXx2ejErjnG1MAGQQmqarcH_81jukXLsAzie25sQVQNyqIvFfP-5dJoGmPsbqFN/s72-c/3_1_1A.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-7692207121827613584</id><published>2011-04-25T07:00:00.000-07:00</published><updated>2011-04-25T07:00:19.830-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Oncology"/><title type='text'>NEW Breast Cancer Treatment Launched in the UK</title><summary type="text">

A new drug for the treatment of advanced or metastatic breast cancer is launched today in the UK prior to its roll out across Europe. 

Halaven™ (eribulin) is a novel treatment for patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced. Prior therapy should have included two common types of chemotherapy, an </summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/7692207121827613584'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/7692207121827613584'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2011/04/new-breast-cancer-treatment-launched-in.html' title='NEW Breast Cancer Treatment Launched in the UK'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgL7mwRgp6Iu4RH2DlKKfbNBo8569l9FcPp4XRJN5BjTif5h49Phyphenhyphen71J1RAvkkuoukHvYZPNJW3aIaYorYhmmbnMsuFDAUNfdkQcPr5HeiusKyv5kDZW1L0LLUwKfE3jeajujcD4OlvgNeb/s72-c/3B6C7BD15D5B5C3A64349A_Large.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-4659123357105352246</id><published>2011-04-25T06:59:00.000-07:00</published><updated>2011-04-25T06:59:43.161-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Nephrology"/><title type='text'>Intensive Control of Hypertension in Nephropathic Patients</title><summary type="text">



In the AASK (African-American Study of Kidney Disease and Hypertension) trial, 1094 non-diabetic, black patients, with hypertension-related nephropathy, have been examined, randomizing them to a standard or intensive anti-hypertension treatment. In spite of the average pressure value obtained through intensive treatment (130/78 vs. 141/86 mmHg), the obtained composed outcome– a reduction of </summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/4659123357105352246'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/4659123357105352246'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2011/04/intensive-control-of-hypertension-in.html' title='Intensive Control of Hypertension in Nephropathic Patients'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh8oPcr4RwxZv_YmFKhccRXLM10uY227MDP7FPQ3YyVa9Vs0UKh1NbHHMcMoMCWubCRjrGnGfkVbNAAkdYHsKfRjyF0KnPFuRAg-8ywNX8XZH1hbwXrOxXr6iuJVLs4hvcRNQ7soV_uXgwX/s72-c/EM00001.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-4761974502186481464</id><published>2011-04-23T15:01:00.001-07:00</published><updated>2011-04-23T15:01:23.111-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Dietetics and Nutrition"/><title type='text'>Low-Carbohydrate or Low-Fat Diet?</title><summary type="text">



Trials published up to now on the comparison between low-carbohydrate and low-fat diet have considered short-term results, so now, in the USA, the results from a 2-year trial are published, where 307 obese adults (average BMI 36 kg/ m2) have been randomized to a low-carbohydrate diet with no fat restriction or to a low-fat diet (about 30% of calories derived from fats). All participants have </summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/4761974502186481464'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/4761974502186481464'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2011/04/low-carbohydrate-or-low-fat-diet.html' title='Low-Carbohydrate or Low-Fat Diet?'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg9XvjpZLgFkLUAtLzGBoeAqxWYLLfI-se6RMc9npcqLEnLnHVDZKjOrihT43QJIWNkntH6rog8xemxBeOYw6BebO2onUloxhfN_Udd2DdbnchDfFO7Tyl9JT0AQ9_MtLCMK6gFum-Q1_v-/s72-c/low+carbohydrate+girl.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-8288103948657968926</id><published>2011-04-23T15:01:00.000-07:00</published><updated>2011-04-23T15:01:01.739-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Diabetology"/><title type='text'>Waist Circumference and Mortality</title><summary type="text">



Waist circumference, as an expression of central adiposity, is associated with insulin resistance, with type 2 diabetes, with dyslipidemia and with coronary artery diseases, with the result that there is an evident relation between waist measure and life expectation. This relation is independent from BMI and it has been shown by many trials, but the direct relationship between waist </summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/8288103948657968926'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/8288103948657968926'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2011/04/waist-circumference-and-mortality.html' title='Waist Circumference and Mortality'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEigJFIfS02jLG3nq6UonBH4TS7oxHo9T0EgcxnAArumqhlyDXi00xQ1s5KwHEvZMyND69CDw-yxeRGQ3-201w11gV3y1P1rOs0czmYR3x3E9WoQNO6Qt-UA5MlCI8NZ2Kd7W_gqietCM-sc/s72-c/waist_circumference_300.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-8228829865694231752</id><published>2011-04-20T09:54:00.000-07:00</published><updated>2011-06-25T10:44:45.678-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="CARDIOTHORACIC SURGERY"/><title type='text'>Left Ventricular Assist Device Exchange: Replacement of a HeartMate XVE with a HeartMate II Device</title><summary type="text">By Mehmet H. Akay, MD, Igor D. Gregoric, MD, William E. Cohn, MD and O. H. Frazier, MD 
In the United States, at least 5 million persons have heart failure at any given time, and more than 550,000 new cases of heart failure are diagnosed each year. Almost 20% of heart failure patients require intravenous inotropic therapy, left ventricular assist device (LVAD) therapy, and/or cardiac </summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/8228829865694231752'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/8228829865694231752'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2011/04/left-ventricular-assist-device-exchange.html' title='Left Ventricular Assist Device Exchange: Replacement of a HeartMate XVE with a HeartMate II Device'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author></entry><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-1550113724949498487</id><published>2011-04-20T09:18:00.001-07:00</published><updated>2011-04-20T09:58:47.140-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Oncology"/><title type='text'>Treatment of Prostate Cancer with Low PSA Value</title><summary type="text">



After the introduction of PSA test, many more prostate cancers are discovered, most of which are not invasive, so survival at 5 years in these subjects approaches 100%. For this reason, researchers have considered the problem of overdiagnosis and consequent excessive treatment. In order to study the matter in depth, the data from a national database concerning about 124,000 patients affected </summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/1550113724949498487'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/1550113724949498487'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2011/04/treatment-of-prostate-cancer-with-low.html' title='Treatment of Prostate Cancer with Low PSA Value'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgi6-khOjPYnzQ-Z1kSsOAcJ5vTtcyCD0GnmxDsw6kfr3ZHWYHz2B379T1pFPu676xjwBsBzWx8QtNKLGEl41uKWANJVxCMKBDLf3ebb4mgYGdfXwRK-oaxxc5tkCM3ZQoaRQPqLhcStxuM/s72-c/prostate-cancer-treatment.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-4041497810713796761</id><published>2011-04-20T09:18:00.000-07:00</published><updated>2011-04-20T10:00:06.745-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Neurology"/><title type='text'>New Therapeutical Target in Alzheimer’s Disease</title><summary type="text">



Alzheimer’s disease is characterized by the overproduction of plaques formed by beta-amyloid, which can be contrasted through the use of proteins belonging to the family of alpha-secretase. In a trial performed by MIT, some rats with an overproduction of beta-amyloid (with consequent behavioural and cognitive alterations very similar to the ones in Alzheimer’s disease) have been matched with </summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/4041497810713796761'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/4041497810713796761'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2011/04/new-therapeutical-target-in-alzheimers.html' title='New Therapeutical Target in Alzheimer’s Disease'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjWNvjLGGb2i5-tWNJAhZ7FcPqEvEIIZdDqWbSixoXLStTfKLF2FXz2q1ToBNJX4D23H5EhLwAgWQ8tjhmQWFKb7aC4K_N8DR_FDuzPMLvtFzypzxa-3eSwSRFzSQ-lX5TpBB4gBgGaGlyE/s72-c/brain_250.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-766313438575015986</id><published>2011-04-20T09:17:00.000-07:00</published><updated>2011-04-20T09:17:52.098-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Neurology"/><title type='text'>Cerebral Biopsies and Dementia</title><summary type="text">



In the cases where it is not possible to explain the occurrence of a rapid and progressive cognitive decline through usual non-invasive examinations, the use of cerebral biopsy has been proposed. In a trial performed by Emory University in Atlanta, some neurosurgeons have re-examined the medical records of 51 adults undergoing cerebral biopsy between 1999 and 2008 to determine the causes of </summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/766313438575015986'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/766313438575015986'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2011/04/cerebral-biopsies-and-dementia.html' title='Cerebral Biopsies and Dementia'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj2cMfCkNY0-etkNSFFFiqEclsPhSvb4YZZzpli9gbiNz80rUWKb0bUodrs6g1yMHljqw63Uv5o7Qmup05D2Z_LxdbonpQBBDP4R77T6ngpDt0hFC0rbqRoYV4zgTT1RfGJVWIQ2eUtrdFw/s72-c/F2.large.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-5164812799074947057</id><published>2011-04-14T15:43:00.001-07:00</published><updated>2011-04-14T15:43:41.706-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Pharmacology"/><title type='text'>Sibutramine and Cardiovascular Events</title><summary type="text">



Weight loss is fundamental for the prevention of cardiovascular events, so trials to find effective solutions to overweight and obesity are more and more frequently performed. In this trial, sponsored by pharmaceutical industry, over 10,000 subjects with an excess of weight and with known cardiovascular risk factors or with type 2 diabetes and at least another risk factor have been collected.</summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/5164812799074947057'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/5164812799074947057'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2011/04/sibutramine-and-cardiovascular-events.html' title='Sibutramine and Cardiovascular Events'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhWVeE8FT7eIz6qcxhMPQAmFMSX6o6GPctAcOZUOTPeMNtSZFKqePuKJWE5FBnVF-CEbi1_aSf7XuvW1BqEExAlhMvl-ZwvyPBR9qadLQNtomptUF5CwrzgoNqBf2dZ2DfcQ6BFnhnGR7Yy/s72-c/diet_pills_250x251.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-3405143871188900099</id><published>2011-04-14T15:43:00.000-07:00</published><updated>2011-04-14T15:43:01.304-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Oncology"/><title type='text'>Adjuvant Endocrine Therapy in Breast Cancer</title><summary type="text">



According to the results published in 2004, the American Society of Clinical Oncology (ASCO) has updated its guidelines on the treatment of breast cancer, focusing its attention on the use of tamoxifen and of aromatase inhibitors. The most important points are the following: - women with cancers positive to estrogen receptors should use aromatase inhibitors, both as a primary adjuvant therapy</summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/3405143871188900099'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/3405143871188900099'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2011/04/adjuvant-endocrine-therapy-in-breast.html' title='Adjuvant Endocrine Therapy in Breast Cancer'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgFGnE8B_ius4V-7Qye3TiUDs-OCZV3XaPc1SjzgRjkYLT4Pf_ImQdNhiVqN-kmdbxQI6NbqXZ12RedomWHfvhCN-P76P_QuaZlP_jkjbmA1CBpl5bhPquNH0Vgaq7oikpTgUC2XQmDQ8tR/s72-c/New-Treatment-for-Breast-Cancer.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-3673538409400356058</id><published>2011-04-11T14:54:00.000-07:00</published><updated>2011-04-11T14:54:46.548-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Cardiology"/><title type='text'>Aorta Diameter in Athletes</title><summary type="text">



It is not always easy to distinguish modifications occurring in the  heart of athletes from the ones which are real heart diseases: for  example, ventricular left remodeling can be taken for hypertrophy and  the same difficulty is to be seen in the evaluation of aortic root  diameter, normally considered a physiologic consequence of the increased  heart output. On this topic, in athletes, a </summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/3673538409400356058'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/3673538409400356058'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2011/04/aorta-diameter-in-athletes.html' title='Aorta Diameter in Athletes'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj5K-5G8xQXTbA4OE0mAvXIk8HzEZZudYtOF-XqfaW8EWOB_5aq3IXNA5Y2dbQp-ENHN9KyEb9mbPoNoGffm-2ZKGc12BbmwM5RkvtacJ9oalrz3rBHhtEVP5E_Jp5bf3tcwb9cK2i7hUAm/s72-c/porto19377.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-2949878265920291424</id><published>2011-04-11T14:53:00.000-07:00</published><updated>2011-04-11T14:53:38.888-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Diabetology"/><title type='text'>Weekly Exenatide</title><summary type="text">




In type 2 diabetes, you can use incretin-mimetic drugs to stimulate  insulin secretion and mitigate glucagone release, slowing gastric  emptying at the same time. Among these ones, exenatide (an agonist of  glucagone-like peptide-1 ( GLP-1) receptors) needs one-two daily  administrations, so a long-acting formulation is being studied, with a  weekly administration. Sitagliptin (an inhibitor </summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/2949878265920291424'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/2949878265920291424'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2011/04/weekly-exenatide.html' title='Weekly Exenatide'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhuV4nzQyWMZWSI26a0Zb9gwOwDYLwa6UbTTF67oaIZYe2RG5OViFhWtgRIBmLoI2HbKQrLuq9DJTv1LFCZrcQrnq5mp5NLvBMxl571pwnQ-aUuLXil0kQb9Lup99-GRnDfPEJdaJTmoHnE/s72-c/person_diabetes.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-6915769450546585061</id><published>2011-03-27T16:35:00.000-07:00</published><updated>2011-03-27T16:35:20.401-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Endocrinology"/><title type='text'>Tiroxine and Cognitive Capability in Subclinical Hypothyroidism</title><summary type="text">

In adults with subclinical hypothyroidism (increased TSH and normal  fT4), is the administration of thyroxine supplementation capable to  improve cognitive function? In order to answer this question, an English  trial has been performed where 94 subjects over 64 years of age with  subclinical hypothyroidism have been treated with thyroxine (up to TSH  normalization) or placebo. At enrolment, </summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/6915769450546585061'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/6915769450546585061'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2011/03/tiroxine-and-cognitive-capability-in.html' title='Tiroxine and Cognitive Capability in Subclinical Hypothyroidism'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg012DWEQx0EcAVDmLcI4bYyZLUTppI17mnSMWhoU404OZVEGoihiYTcYMRz7OHwVkhMofYRudBcRw7N0t1JsSYpi5oEf0nD9NJgGsKRzZnbr3ESy82QzxFy4ifPY9hWwD3D_Q8fmJm1u8o/s72-c/F1.medium.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-3365081682713532646</id><published>2011-03-27T16:32:00.000-07:00</published><updated>2011-03-27T16:32:52.274-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Pharmacology"/><title type='text'>Bupropion and Naltrexone to Lose Weight</title><summary type="text">

In the equipment of drugs to obtain a weight loss, there are some  products which really produce a weight loss but which are not used for  this reason because of their heavy side effects, such as, for example,  rimonabant (an antagonist of cannabinoid receptors, recently retired  from the market) and, partly, sibutramine. At present, the association  of bupropion and naltrexone is being studied</summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/3365081682713532646'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/3365081682713532646'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2011/03/bupropion-and-naltrexone-to-lose-weight.html' title='Bupropion and Naltrexone to Lose Weight'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhabE3OM9rXpyHctpPEhl_jO8XgmicK8tBccLeW7IGYes1so2GJpUX-g4ThyJwvMkVdAe0m1NDijUKNN6xcfofTy5q7X0LQ8cosP54IyBTAvRzq_Q0eD2HyAAqdNByqeehW4jt2v9u6JQMP/s72-c/madeinchina.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-3955449131311121053</id><published>2011-03-23T11:40:00.000-07:00</published><updated>2011-03-23T12:49:04.733-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Orthopaedics"/><title type='text'>Menopausal Osteoporosis</title><summary type="text">

Despite there is not drugs capable to reduce the risk of fractures of  50%-70% after 6-12 months of treatment, postmenopausal osteoporosis  often remains not recognized and consequently not treated, with easily  foreseeable consequences. The North American Menopause Society (NAMS),  in its declarations in 2010, affirms that all women in post-menopause  should be assessed for risk factors </summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/3955449131311121053'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/3955449131311121053'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2011/03/menopausal-osteoporosis.html' title='Menopausal Osteoporosis'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhMCKIJcECx2kXlAD5XAp2Ev6w0ytrQtBD1u1ikJRnVdQgt5E1gsSDt6ecBdXQepYtFZO9Hquo4-jSgS3Tm249hoKbwi3R_VPhnz7QVc_6hnv9w2d9vn0tJix1oP_7t1Hy79TTnRS6QCU-t/s72-c/Osteoporosis-bone-density.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-6239231037921462366</id><published>2011-03-23T11:37:00.000-07:00</published><updated>2011-03-23T12:47:21.689-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Rheumatology"/><title type='text'>Incidence and Prevalence of Rheumatoid Arthritis in Women</title><summary type="text">

Even if genetic factors certainly have an important role, at the  basis of the incidence and prevalence of rheumatoid arthritis, no doubt,  there are other factors. In order to verify the extent of this disease,  some researchers at Mayo Clinic have examined the data relative to  cases of rheumatoid arthritis diagnosed in Olmsted, Minnesota, between  1995 and 2007. A slight increase in the </summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/6239231037921462366'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/6239231037921462366'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2011/03/incidence-and-prevalence-of-rheumatoid.html' title='Incidence and Prevalence of Rheumatoid Arthritis in Women'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgFuK8t88KL_VPW3CUh4PAwEjULxFzddLXSo_uC-9ifCbUWsrWQwChYMgoAutU6hm4AWh0LG0PWROmXzK42D6GOqMn5WlglkaP62xCHS-MVM8X-C6uSmlTTbkngFdo0w9MhIPtNhGe4Ao-Z/s72-c/rheumatoid-arthritis.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-5243484110268352177.post-5280492758050118374</id><published>2011-03-21T11:32:00.000-07:00</published><updated>2011-03-23T12:12:45.523-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Pediatrics"/><title type='text'>Skin Infections in Children</title><summary type="text">

The treatment of skin and soft-tissue infections in pediatrics has  been complicated  by the constant increase of antibiotic resistance by  Staphylococcus aureus. With a retrospective, case-control trial, the  efficacy of a treatment, performed in Philadelphia through  beta-lactamines, clindamycin or trimetoprim-sulphametoxazole (TMP-SMX)  was evaluated in 2096 children (between 0 and 21) with </summary><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/5280492758050118374'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5243484110268352177/posts/default/5280492758050118374'/><link rel='alternate' type='text/html' href='http://doc-logic.blogspot.com/2011/03/skin-infections-in-children.html' title='Skin Infections in Children'/><author><name>DOC</name><uri>http://www.blogger.com/profile/04277052174369268425</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhbWn-dBDTKrJPr4kUAGX_LBIoid4zPyAbjBkzOstE9R1lkV8QIcxU5XH9fBgLZoYz0VbfVmbqgiVGUJUUuPntsa9yYO7_l4rLFEPDqnN7tHCOSq7xCFWFz5rSLNL96yjkWDfywRko0uHeO/s72-c/vai_impetigo_progress.jpg" height="72" width="72"/></entry></feed>